Praxis Precision (PRAX) Medicines is looking to raise $400M from an overnight sale of shares and warrants priced between $152.00-$157.00 per share, according to Bloomberg’s Anthony Hughes, citing people familiar with the matter.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision announces common stock and warrants offering, no amount given
- Buy Rating for Praxis Precision Medicines Driven by Ulixacaltamide’s Promising Phase III Results and Market Potential
- Praxis Precision price target raised to $441 from $83 at JonesResearch
- Promising Potential of Praxis Precision Medicines: Buy Rating on Ulixacaltamide’s Strong Phase 3 Results and Market Opportunity
- Praxis Precision price target raised to $232 from $115 at H.C. Wainwright